Ginger
Phase 3Small molecule
Ginger is one of 11 small molecule programs targeting Pain Management. It is currently in Phase 3.
1
Indications
13
Total Trials
3
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Pain Management
#DrugCompanyPhaseTrials
1Naropin
FFresenius Kabi USA, LLC
Approved
Keterol
PPamukkale University
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 2
Bupivacaine-Epinephrine
UUniversity of Aarhus
Phase 3
Ginger
UUniversity of Rochester
Phase 3
Psilocybin
COMPASS PathwaysPhase 1
Bupivacain
IIstanbul University
Preclinical
Bupivacaine %0.25 (isobaric)
UUniversity of Novi Sad
Preclinical
Standard Preparation
LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Preclinical
Pennsaid
MMallinckrodt
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nausea and vomiting3 trials
Ginger Control of Chemotherapy Induced Nausea and Vomiting
Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT00065221·180 enrolled
Vertigo1 trial
Efficacy1 trial
6 more indications
Chemotherapy-induced nausea and vomiting1 trial
Back pain1 trial
Pain Management1 trial
the Efficacy of Ginger Powder as an Analgesic for Intraoperative and Post- Endodontic Pain Management
Not yet recruiting·—·Phase 3·NCT06439212·50 enrolled
Cesarean Section1 trial
Efficacy of Ginger in the Prevention of Abdominal Distention in Post Cesarean Section Patient
Completed·—·Phase 4·NCT02809027·178 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ginger. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Rochester